Diagnostic and Therapeutic Implications of Histone Epigenetic Modulators in Breast Cancer

被引：3

作者：

Walsh, Louise ^{[1
,2
]}

Gallagher, William M. ^{[3
,4
]}

O'Connor, Darran P. ^{[1
]}

Chonghaile, Triona Ni ^{[2
]}

机构：

[1] Royal Coll Surgeons Ireland, Dept Mol & Cellular Therapeut, Dublin 2, Ireland

[2] Royal Coll Surgeons Ireland, Dept Physiol & Med Phys, Dublin 2, Ireland

[3] Univ Coll Dublin, Canc Biol & Therapeut Lab, UCD Sch Biomol & Biomed Sci, UCD Conway Inst, Dublin 4, Ireland

[4] OncoMark Ltd, NovaUCD, Belfield Innovat Pk, Dublin 4, Ireland

来源：

EXPERT REVIEW OF MOLECULAR DIAGNOSTICS | 2016年 / 16卷 / 05期

关键词：

Breast cancer; epigenetics; diagnostic; resistance; histone deacetylases; BET proteins and polycomb proteins; BET BROMODOMAIN INHIBITION; GROUP PROTEIN EZH2; EPITHELIAL-MESENCHYMAL TRANSITION; SUBEROYLANILIDE HYDROXAMIC ACID; ACUTE LYMPHOBLASTIC-LEUKEMIA; ESTROGEN-RECEPTOR; PHASE-II; BASAL-LIKE; SELECTIVE-INHIBITION; DNA METHYLATION;

D O I：

10.1586/14737159.2016.1156534

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Breast cancer is the most common cancer in women and great advancements have been made for individualised patient treatment. Through understanding the underlying altered biology in the different subtypes of breast cancer, targeted therapeutics have been developed. Unfortunately, resistance to targeted therapy, intrinsic or acquired, is a recurring theme in cancer treatment. Epigenetic-mediated resistance to targeted therapy has been identified across different types of cancer. In addition, tumorigenesis has also been linked to altered expression of epigenetic modifiers. Due to the reversible nature of epigenetic modifications, epigenetic proteins are appealing as therapeutic targets in both the primary and relapsed/resistant setting. In this review, we will discuss the current state of targetable epigenetic histone modifications and their diagnostic and therapeutic implications in breast cancer.

引用

页码：541 / 551

页数：11

共 50 条

[1] Peptides as epigenetic modulators: therapeutic implications
Yorick Janssens
Evelien Wynendaele
Wim Vanden Berghe
Bart De Spiegeleer
[J]. Clinical Epigenetics, 2019, 11
[2] Peptides as epigenetic modulators: therapeutic implications
Janssens, Yorick
Wynendaele, Evelien
Vanden Berghe, Wim
De Spiegeleer, Bart
[J]. CLINICAL EPIGENETICS, 2019, 11 (1)
[3] Therapeutic Implications of Epigenetic Signaling in Breast Cancer
Oh, Tae Gyu
Wang, Shu-Ching M.
Muscat, George E. O.
[J]. ENDOCRINOLOGY, 2017, 158 (03) : 431 - 447
[4] Epigenetic Modulators as Therapeutic Agents in Cancer
Patnaik, Eshaan
Madu, Chikezie
Lu, Yi
[J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (19)
[5] The Histone Acetylation Modifications of Breast Cancer and their Therapeutic Implications
Guo, Pingping
Chen, Wenqi
Li, Huiyu
Li, Meiying
Li, Lisha
[J]. PATHOLOGY & ONCOLOGY RESEARCH, 2018, 24 (04) : 807 - 813
[6] Clinical and Therapeutic Implications of Histone Acetylation in Breast Cancer
Riaz, S. K.
Saeed, M.
Malik, M. F. A.
[J]. WEST INDIAN MEDICAL JOURNAL, 2016, 65 (02): : 337 - 344
[7] Epigenetic and breast cancer therapy: Promising diagnostic and therapeutic applications
Sher, Gulab
Salman, Nadia Aziz
Khan, Abdul Q.
Prabhu, Kirti S.
Raza, Afsheen
Kulinski, Michal
Dermime, Said
Haris, Mohammad
Junejo, Kulsoom
Uddin, Shahab
[J]. SEMINARS IN CANCER BIOLOGY, 2022, 83 : 152 - 165
[8] Epigenetic Modulations in Breast Cancer: An Emerging Paradigm in Therapeutic Implications
Sarkar, Shilpi
Venkatesh, Dheepika
Kandasamy, Thirukumaran
Ghosh, Siddhartha Sankar
[J]. FRONTIERS IN BIOSCIENCE-LANDMARK, 2024, 29 (08):
[9] Epigenetic modulators as therapeutic targets in prostate cancer
Inês Graça
Eva Pereira-Silva
Rui Henrique
Graham Packham
Simon J. Crabb
Carmen Jerónimo
[J]. Clinical Epigenetics, 2016, 8
[10] Epigenetic modulators as therapeutic targets in prostate cancer
Graca, Ines
Pereira-Silva, Eva
Henrique, Rui
Packham, Graham
Crabb, Simon J.
Jeronimo, Carmen
[J]. CLINICAL EPIGENETICS, 2016, 8

← 1 2 3 4 5 →